Диссертация (1154797), страница 17
Текст из файла (страница 17)
HOTStudy Group // Lancet. 1998;351(9118):1755–176275.Herrera-Anazco P.et al. Prevalence of chronic kidney disease in Peruvian primarycare setting. BMC Nephrology 2017;18:246-5276.Herrera-Anazco P., Benites-Zapata V., Leon-Yurivilca I. et al. Chronic kidneydisease in Peru: a challenge for a country with an emerging economy. J BrasNefrol. 2015;37(4):507–8.77.Herrera-Anazco P.et al. Diabetes mellitus and diabetic nephropathy in Peru.Nefrologia, Dialisis Trasplante. 2015;35(4):229–37.78.Hill N., Fatoba S., Oke J. et al. Global prevalence of chronic kidney disease – asystematic review and meta-analysis. PLoS One.
2016;11(7):e0158765.79.Hirsch S., Hirsch J., Bhatt U. et al. Tolerating increases in the serum creatininefollowing aggressive treatment of chronic kidney disease, hypertension andproteinuria: pre-renal success. Am J Nephrol 2012;36:430–7.80.http://www.kidney-international.org/81.Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group.KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int, (Suppl)2012;2:1–138.12382.Inker L.A., Astor B.C., Fox C.H. et al. KDOQI US commentary on the 2012KDIGO clinical practice guideline for the evaluation and management of CKD.Am J Kidney Dis.
2014;63(5):713–3583.Inker L.A., Levey A.S., Pandya K. et al. Early change in proteinuria as asurrogate end point for kidney disease progression: an individual patient metaanalysis. Am J Kidney Dis 2014;64:74–85.84. Interdisciplinary Chronic Disease Collaboration A Decade After the KDOQICKD Guidelines: A Perspective From Canada // Am J Kidney Dis.2012;60(5):723–4.85.Ishani A., Grandits G.A., Grimm R.H. et al. Association of single measurementsof dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with25-year incidence of end-stage renal disease in the multiple risk factorintervention trial.
J Am Soc Nephrol. 2006;17(5):1444-52.86.Jamerson K., Weber M.A., Bakris G.L. et al. ACCOMPLISH Trial Investigators.Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-riskpatients. N Engl J Med 2008;359:2417–28.87.James M.T., Hemmelgarn B.R., Tonelli M. Early recognition and prevention ofchronic kidney disease. Lancet 2010;375:1296–309.88.James P.A., Oparil S., Carter B.L. et al. 2014 Evidence-based guideline for themanagement of high blood pressure in adults: report from the Panel MembersAppointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311:507-2089.Kastarinen M., Antikainen R., Peltonen M. et al. Prevalence, awareness andtreatment of hypertension in Finland during 1982– 2007 // J.
Hypertens. 2009;2788:1552-9.90.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management ofChronic Kidney Disease. Kidney Int (Suppl.) 2013;3:1–150.12491.Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group.KDIGO Clinical Practice Guideline for Lipid Management in Chronic KidneyDisease. Kidney Int. (Suppl.) 2013;3:259–305.92.Kjeldsen S.E., Jamerson K.A., Bakris G.L. et al. Predictors of systolic bloodpressure <140 mmHg and systolic blood pressure level by randomly assignedtreatment group (benazepril plus amlodipine or hydrochlorothiazide) in theACCOMPLISH Study. Blood Press.
2012;21:82-87.93.Kostis J.B., Cabrera J., Cheng J.Q. et al. Association between chlorthalidonetreatment of systolic hypertension and long-term survival. JAMA 2011;306:258893.94.Ku E., Glidden D.V., Johansen K.L. et al. Association between strict bloodpressure control during chronic kidney disease and lower mortality after onset ofend-stage renal disease. Kidney Int.
2015;87:1055–1060.95.Lamb E.J., Stevens P.E. Estimating and measuring glomerular filtration rate:methods of measurement and markers for estimation. Curr Opin NephrolHypertens 2014;23:258–66.96.Levey A.S., Becker C., Inker L.A. Glomerular fi ltration rate and albuminuria fordetection and staging of acute and chronic kidney disease in adults: a systematicreview. JAMA 2015;313:837–46.97.Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimateglomerular filtration rate. Ann Intern Med 2009;150:604-12.98.Lithell H., Hansson L., Skoog I.
et al. The Study on Cognition and Prognosis inthe Elderly (SCOPE): principal results of a randomized double-blind interventiontrial. J Hypertens 2003;21:875–86.99.Llisterri J.L., Rodriguez-Roca G.C., Escobar C. et al. on behalf of the WorkingGroup of Arterial Hypertension of the Spanish Society of Primary CarePhysicians (Group HTASEMERGEN); and the PRESCAP 2010 investigators.Treatment and blood pressure control in Spain during 2002–2010 // J. Hypertens.2012; 30:2425-31.125100. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension: the task force for the management ofarterial hypertension of the European Society of hypertension (ESH) and of theEuropean Society of Cardiology (ESC).
J Hypertens 2013;31:1281-357101. Mangrum A.J., Bakris G.L. Angiotensin-converting enzyme inhibitors andangiotensin receptor blockers in chronic renal disease: safety issues. SeminNephrol 2004;24:168–75102. Mann J.F., Schmieder R.E., McQueen M. et al. Renal outcomes withtelmisartan, ramipril, or both in people at high vascular risk (the ONTARGETstudy): a multicentre, randomized, double-blind controlled trial. Lancet2008;372:547–53.103. Masson P., Webster A.C., Hong M. et al. Chronic kidney disease and the riskof stroke: a systematic review and meta-analysis. Nephrol Dial Transplant 2015;30:1162–69.104. Matsushita K., van der Velde M., Astor B.C. et al. Chronic Kidney DiseasePrognosis Consortium.
Association of estimated glomerular filtration rate andalbuminuria with all-cause and cardiovascular mortality in general populationcohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.105. McAlister F.A., Wilkins K., Joffres M. et al. Changes in the rates of awareness,treatment and control of hypertension in Canada over the past two decades //CMAJ. 2011;183:1007-13.106.
McClellan W. The epidemic of renal disease – what drives it and what can bedone? // Nephrol Dial Transplant. 2006;21(6):1461-1464.107. Mills K.T., Xu Y., Zhang W. et al. A systematic analysis of worldwidepopulation-based data on the global burden of chronic kidney disease in 2010.Kidney Int.
2015;88:950–7.108. Morony S., Flynn M., McCaff ery K.J. et al. Readability of written materialsfor CKD patients: a systematic review. Am J Kidney Dis 2015;65:842–50.126109. Morton R.L., Schlackow I., Mihaylova B. et al.The impact of socialdisadvantage in moderate-to-severe chronic kidney disease: an equity-focusedsystematic review. Nephrol Dial Transplant 2016;31:46–56.110. Multiple Risk Factor Intervention Trial Research Group. Circulation 1990;82:1616–28111. National Kidney Foundation. K/DOQI clinical practice guidelines for chronickidney disease: evaluation, classification, and stratification.
Am J Kidney Dis2002; 39(1):1–266.112. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetesand CKD: 2012 update. Am J Kidney Dis 2012;60(5):850–886.113. Ninomiya T., Perkovic V., de Galan B.E. Albuminuria and Kidney FunctionIndependently Predict Cardiovascular and Renal Outcomes in Diabetes.
J Am SocNephrol. 2009;20(8):1813–1821.114. O’Lone E., Connors M., Masson P. et al. Cognition in people with end-stagekidney disease treated with hemodialysis: a systematic review and meta-analysis.Am J Kidney Dis 2016;67:925–35.115. O’Seaghdha C.M., Hwang S.J., Upadhyay A. et al.
Predictors of IncidentAlbuminuria in the Framingham Offspring Cohort. Am J Kidney Dis. 2010 Nov;56(5): 852–860.116. Ojima M., Igata H., Tanaka M. et al. In vitro antagonistic properties of a newangiotensin type 1 receptor blocker, azilsartan, in receptor binding and functionstudies. J Pharmacol Exp Ther 2011;336:801-8.117. PalaniappanL.,CarnethonM.,FormannS.Associationbetweenmicroalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens.2003;16(11):952-8.118.
Park J., Baek H., Jung H. CKD and health-related quality of life: the Koreanational health and nutrition examination survey. Am J Kidney Dis 2016;67:851–60.119. Parving H.H., Brenner B.M., McMurray J.J. et al. Cardiorenal endpoints in atrial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–13.127120. Patel A., MacMahon S., Chalmers J.et al.
Effects of a fixed combination ofperindopril and indapamide on macrovascular and microvascular outcomes inpatients with type 2 diabetes mellitus (the ADVANCE trial): a randomisedcontrolled trial. Lancet 2007;370:829–40.121. Perazella M. The urine sediment as a biomarker of kidney disease. Am JKidney Dis 2015;66:748–55.122. Perkovic V., Cass A., Patel A. et al. High prevalence of chronic kidney diseasein Thailand. Kidney Int 2008;73:473–479.123. Peterzan M.A., Hardy R., Chaturvedi N. et al. Meta-analysis of dose-responserelationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide onblood pressure, serum potassium, and urate.
Hypertension 2012;59:1104–9124. Prescribing information. Edarbyclor (azilsartan medoxomil/chlorthalidone).Deerfield,IL:TakedaPharmaceuticalsAmerica,Inc.,October2012.www.edarbihcp.com/ (accessed 2012 Oct 30).125. Prevalence of low glomerular filtration rate in nondiabetic Americans: ThirdNational Health and Nutrition Examination Survey (NHANES III) // J Am SocNephrol. – 2002;13(5):1338-1349.126.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
